Lisata Therapeutics, Inc. (NASDAQ:LSTA) Short Interest Update

Lisata Therapeutics, Inc. (NASDAQ:LSTA) was the recipient of a large increase in short interest in February. As of February 28th, there was short interest totalling 40,100 shares, an increase of 50.2% from the February 13th total of 26,700 shares. Currently, 0.6% of the company’s shares are sold short. Based on an average trading volume of 41,400 shares, the short-interest ratio is currently 1.0 days.

Institutional Investors Weigh In On Lisata Therapeutics

A hedge fund recently bought a new stake in Lisata Therapeutics stock. Citadel Advisors LLC bought a new position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 23,273 shares of the company’s stock, valued at approximately $69,000. Citadel Advisors LLC owned about 0.28% of Lisata Therapeutics at the end of the most recent reporting period. 8.94% of the stock is currently owned by hedge funds and other institutional investors.

Lisata Therapeutics Stock Down 0.4 %

LSTA traded down $0.01 during trading hours on Monday, hitting $2.38. The stock had a trading volume of 3,291 shares, compared to its average volume of 21,722. Lisata Therapeutics has a 1 year low of $2.05 and a 1 year high of $4.20. The company’s fifty day simple moving average is $2.78 and its 200 day simple moving average is $2.87. The stock has a market cap of $20.52 million, a PE ratio of -0.95 and a beta of 1.16.

Lisata Therapeutics (NASDAQ:LSTA) last posted its earnings results on Thursday, February 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.21. The company had revenue of $1.00 million for the quarter. As a group, equities analysts expect that Lisata Therapeutics will post -2.66 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Lisata Therapeutics in a research note on Wednesday, December 11th.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.